Xeris Pharmaceuticals (NASDAQ:XERS) posted its quarterly earnings data on Thursday. The company reported ($1.22) EPS for the quarter, topping analysts’ consensus estimates of ($1.23) by $0.01, Fidelity Earnings reports. The company had revenue of $0.32 million for the quarter, compared to analyst estimates of $0.20 million. Xeris Pharmaceuticals had a negative return on equity of 107.65% and a negative net margin of 4,876.50%.
Xeris Pharmaceuticals stock traded down $0.21 on Friday, reaching $8.02. The company’s stock had a trading volume of 109,200 shares, compared to its average volume of 201,264. The company has a debt-to-equity ratio of 0.39, a quick ratio of 6.00 and a current ratio of 6.00. The company has a market cap of $236.68 million, a price-to-earnings ratio of -1.61 and a beta of -0.49. The business’s fifty day moving average price is $8.76 and its 200 day moving average price is $10.50. Xeris Pharmaceuticals has a twelve month low of $6.85 and a twelve month high of $25.49.
A number of equities analysts have commented on the company. Mizuho reissued a “buy” rating and issued a $22.00 price objective on shares of Xeris Pharmaceuticals in a research note on Friday. Royal Bank of Canada set a $18.00 price objective on Xeris Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Finally, ValuEngine lowered Xeris Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, September 30th.
In other Xeris Pharmaceuticals news, insider Steven Prestrelski sold 27,700 shares of the business’s stock in a transaction on Friday, October 11th. The stock was sold at an average price of $9.00, for a total value of $249,300.00. 7.43% of the stock is currently owned by insiders.
About Xeris Pharmaceuticals
Xeris Pharmaceuticals, Inc, a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps.
Featured Story: Stock Portfolio Tracker
Receive News & Ratings for Xeris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.